使用葡萄糖胺CEST MRI进行代谢性脑成像:体内特征和第一次见解
Michal Rivlin1, Or Perlman2,3, Gil Navon4
1School of Chemistry, Tel-Aviv University, Tel-Aviv, Israel.
Scientific reports
|December 12, 2023
概括
化学交换和转移 (CEST) 的MRI检测了大脑中葡萄糖胺 (GlcN) 的吸收. 这种技术显示出作为一种代谢生物标志物的潜力,用于诊断和监测大脑疾病.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物 生物标志物
- 代谢成像 - 代谢成像
背景情况:
- 化学交换和转移 (CEST) 核磁共振扫描在通过摄取葡萄糖胺 (GlcN) 检测乳腺癌方面已显示出实用性.
- 葡萄糖胺 (GlcN) 是一种安全的食补充剂,具有潜在的治疗应用.
- 监测大脑中的代谢变化对于理解神经系统疾病至关重要.
研究的目的:
- 通过使用CESTMRI在大脑中 GlcN吸收和代谢的检测能力的特征.
- 评估GlcN CEST作为潜在的代谢生物标志物用于大脑疾病.
- 为了研究 GlcN 在大脑中的生物分布和代谢命运.
主要方法:
- 在小鼠中静脉注射GlcN.
- CESTMRI采集和磁化转移比率不对称性 (MTRasym) 分析.
- 13C 脑部提取物的NMR光谱研究用于代谢确认.
- 对CEST信号的洛伦兹多池合适性分析.
主要成果:
- 在GlcN给药后观察到显著升高的CEST大脑信号 (MTRasym),主要在皮质,海马体和乳头.
- 在体内对比度在40分钟内保持稳定,表明持续的GlcN吸收和代谢.
- 13C NMR证实了脑部提取物中的GlcN积累及其代谢产物.
- 在 GlcN 处理后检测到增加的基,胺和继电核Overhauser 效应 (rNOE) 信号组件.
结论:
- GlcN可以穿越血脑屏障 (BBB),并使用CESTMRI在大脑中检测到.
- GlcN CEST MRI 作为评估大脑新陈代谢的敏感方法.
- 这种技术作为一种代谢生物标志物,有望用于诊断和监测各种脑部疾病.
相关概念视频
Brain Imaging
234
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
234
Magnetic Resonance Imaging
5.2K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
5.2K


![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)